We have also reported that the platelet GSK‐3β activity could be a peripheral biomarker for MCI, because it showed increase in T2DM with MCI (T2DM‐MCI) patients compared to T2DM without MCI (T2DM‐nMCI).12, 42, 43, 44. This evidence concerns the gene GSK3B and type 2 diabetes mellitus.